| IMMATICS N.V. |
| Niederlande |
| Gesundheit |
| NL0015285941 / A2P72S |
| 4A3 (Frankfurt) |
| FRA:4A3, ETR:4A3, 4A3:GR |
| - |
| https://immatics.com/ |
|
Immatics N.V. is a biotechnology company dedicated to the discovery and development of T-cell redirecting cancer immunotherapies. The company's primary function is to harness the power of the body's immune system to target and eliminate cancer cells,..
>Volltext.. |
| 1162.58 Mio. EUR |
| 709.1 Mio. EUR |
| 46.77 Mio. EUR |
| -171.57 Mio. EUR |
| -192.58 Mio. EUR |
| -1.57 EUR |
| 15.91 Mio. EUR |
| 351.95 Mio. EUR |
| -178.1 Mio. EUR |
| 10.91 |
| -71.77% |
| -1346.14% |
| - |
| - |
| - |
| - |
| IMMATICS |
| 05.04.26 |
|